174 related articles for article (PubMed ID: 16609057)
1. Immune monitoring of T-cell responses in cancer vaccine development.
Keilholz U; Martus P; Scheibenbogen C
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2346s-2352s. PubMed ID: 16609057
[TBL] [Abstract][Full Text] [Related]
2. Proteomics for monitoring immune responses to cancer vaccines.
Mosca PJ; Lyerly HK; Ching CD; Hobeika AC; Clay TM; Morse MA
Curr Opin Mol Ther; 2003 Feb; 5(1):39-43. PubMed ID: 12669469
[TBL] [Abstract][Full Text] [Related]
3. Local delivery of poxvirus vaccines for melanoma.
Hörig H; Kaufman HL
Semin Cancer Biol; 2003 Dec; 13(6):417-22. PubMed ID: 15001160
[TBL] [Abstract][Full Text] [Related]
4. Melanoma cancer vaccines and anti-tumor T cell responses.
Vujanovic L; Butterfield LH
J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
[TBL] [Abstract][Full Text] [Related]
6. Peptide and dendritic cell vaccines.
Slingluff CL; Engelhard VH; Ferrone S
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2342s-2345s. PubMed ID: 16609056
[TBL] [Abstract][Full Text] [Related]
7. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
8. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
9. Direct detection of cellular immune responses to cancer vaccines.
Mosca PJ; Hobeika AC; Clay TM; Morse MA; Lyerly HK
Surgery; 2001 Mar; 129(3):248-54. PubMed ID: 11231452
[TBL] [Abstract][Full Text] [Related]
10. Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials.
Zaritskaya L; Shafer-Weaver KA; Gregory MK; Strobl SL; Baseler M; Malyguine A
J Immunother; 2009; 32(2):186-94. PubMed ID: 19238018
[TBL] [Abstract][Full Text] [Related]
11. The relevance of cytokines for development of protective immunity and rational design of vaccines.
Chabalgoity JA; Baz A; Rial A; Grille S
Cytokine Growth Factor Rev; 2007; 18(1-2):195-207. PubMed ID: 17347024
[TBL] [Abstract][Full Text] [Related]
12. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
14. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic cancer vaccines: using unique antigens.
Lewis JJ
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14653-6. PubMed ID: 15297620
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
17. Rational peptide-based tumour vaccine development and T cell monitoring.
Scheibenbogen C; Letsch A; Schmittel A; Asemissen AM; Thiel E; Keilholz U
Semin Cancer Biol; 2003 Dec; 13(6):423-9. PubMed ID: 15001161
[TBL] [Abstract][Full Text] [Related]
18. Quantitating therapeutically relevant T-cell responses to cancer vaccines.
Hobeika AC; Clay TM; Mosca PJ; Lyerly HK; Morse MA
Crit Rev Immunol; 2001; 21(1-3):287-97. PubMed ID: 11642610
[TBL] [Abstract][Full Text] [Related]
19. The human T cell response to melanoma antigens.
Romero P; Cerottini JC; Speiser DE
Adv Immunol; 2006; 92():187-224. PubMed ID: 17145305
[TBL] [Abstract][Full Text] [Related]
20. Methods to monitor immune response and quality control.
Whiteside TL
Dev Biol (Basel); 2004; 116():219-28; discussion 229-36. PubMed ID: 15603195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
